(Q36823607)

16 August 2017

Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer (English)

1 reference

multicenter clinical trial

16 August 2017

0 references

1 reference

24

John S McGrath

1 reference

16 August 2017

34

Yair Lotan

1 reference

16 August 2017

7

Laura-Maria Krabbe

1 reference

16 August 2017

26

Shahrokh F Shariat

1 reference

16 August 2017

18

Wassim Kassouf

1 reference

16 August 2017

Homayoun Zargar

1

1 reference

16 August 2017

Patrick N Espiritu

2

1 reference

16 August 2017

Adrian S Fairey

3

1 reference

16 August 2017

Laura S Mertens

4

1 reference

16 August 2017

Colin P Dinney

5

1 reference

16 August 2017

Maria C Mir

6

1 reference

16 August 2017

Michael S Cookson

8

1 reference

16 August 2017

Niels-Erik Jacobsen

9

1 reference

16 August 2017

Nilay M Gandhi

10

1 reference

16 August 2017

Joshua Griffin

11

1 reference

16 August 2017

Jeffrey S Montgomery

12

1 reference

16 August 2017

Nikhil Vasdev

13

1 reference

16 August 2017

Evan Y Yu

14

1 reference

16 August 2017

David Youssef

15

1 reference

16 August 2017

Evanguelos Xylinas

16

1 reference

16 August 2017

Nicholas J Campain

17

1 reference

16 August 2017

Marc A Dall'Era

19

1 reference

16 August 2017

Jo-An Seah

20

1 reference

16 August 2017

Cesar E Ercole

21

1 reference

16 August 2017

Simon Horenblas

22

1 reference

16 August 2017

Srikala S Sridhar

23

1 reference

16 August 2017

Jonathan Aning

25

1 reference

16 August 2017

Jonathan L Wright

27

1 reference

16 August 2017

Andrew C Thorpe

28

1 reference

16 August 2017

Todd M Morgan

29

1 reference

16 August 2017

Jeff M Holzbeierlein

30

1 reference

16 August 2017

Trinity J Bivalacqua

31

1 reference

16 August 2017

Scott North

32

1 reference

16 August 2017

Daniel A Barocas

33

1 reference

16 August 2017

Jorge A Garcia

35

1 reference

16 August 2017

Andrew J Stephenson

36

1 reference

16 August 2017

Jay B Shah

37

1 reference

16 August 2017

Bas W van Rhijn

38

1 reference

16 August 2017

Siamak Daneshmand

39

1 reference

16 August 2017

Philippe E Spiess

40

1 reference

16 August 2017

Peter C Black

41

1 reference

16 August 2017

language of work or name

English

0 references

publication date

23 September 2014

1 reference

16 August 2017

1 reference

16 August 2017

67

1 reference

16 August 2017

241-249

1 reference

16 August 2017

2

1 reference

Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840190

Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer

5 September 2018

1 reference

12 December 2020

Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: the impact of pathologic response on long-term results

1 reference

12 December 2020

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

1 reference

12 December 2020

Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer

1 reference

12 December 2020

Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience

1 reference

12 December 2020

Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group

1 reference

12 December 2020

The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study

1 reference

12 December 2020

10.1016/J.EURURO.2014.09.007

Identifiers

DOI

1 reference

16 August 2017

1 reference

16 August 2017

1 reference